Concordance in measurable residual disease result after first and second induction cycle in acute myeloid leukemia: An outcome- and cost-analysis.
acute myeloid leukemia
earlier detection
guided therapy
measurable residual disease (MRD)
multiparameter flow cytometry (MFC)
prognostic value
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
21
07
2022
accepted:
20
09
2022
entrez:
27
10
2022
pubmed:
28
10
2022
medline:
28
10
2022
Statut:
epublish
Résumé
Measurable residual disease (MRD) measured using multiparameter flow-cytometry (MFC) has proven to be an important prognostic biomarker in acute myeloid leukemia (AML). In addition, MRD is increasingly used to guide consolidation treatment towards a non-allogenic stem cell transplantation treatment for MRD-negative patients in the ELN-2017 intermediate risk group. Currently, measurement of MFC-MRD in bone marrow is used for clinical decision making after 2 cycles of induction chemotherapy. However, measurement after 1 cycle has also been shown to have prognostic value, so the optimal time point remains a question of debate. We assessed the independent prognostic value of MRD results at either time point and concordance between these for 273 AML patients treated within and according to the HOVON-SAKK 92, 102, 103 and 132 trials. Cumulative incidence of relapse, event free survival and overall survival were significantly better for MRD-negative (<0.1%) patients compared to MRD-positive patients after cycle 1 and cycle 2 (
Identifiants
pubmed: 36300090
doi: 10.3389/fonc.2022.999822
pmc: PMC9589259
doi:
Types de publication
Journal Article
Langues
eng
Pagination
999822Informations de copyright
Copyright © 2022 Tettero, Al-Badri, Ngai, Bachas, Breems, van Elssen, Fischer, Gjertsen, van Gorkom, Gradowska, Greuter, Griskevicius, Juliusson, Maertens, Manz, Pabst, Passweg, Porkka, Löwenberg, Ossenkoppele, Janssen and Cloos.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Leukemia. 2016 Oct;30(10):2080-2083
pubmed: 27133827
Leukemia. 2006 Oct;20(10):1783-9
pubmed: 16838027
Blood. 2021 Dec 30;138(26):2753-2767
pubmed: 34724563
Semin Hematol. 2019 Apr;56(2):164-170
pubmed: 30926093
Curr Protoc Cytom. 2019 Dec;91(1):e66
pubmed: 31763792
J Clin Oncol. 2012 Oct 10;30(29):3625-32
pubmed: 22965955
J Clin Oncol. 2015 Apr 10;33(11):1258-64
pubmed: 25732155
JAMA Oncol. 2020 Dec 01;6(12):1890-1899
pubmed: 33030517
Blood Adv. 2021 Feb 23;5(4):1110-1121
pubmed: 33616652
Blood. 2017 Mar 23;129(12):1636-1645
pubmed: 28049642
Blood. 2017 Jan 26;129(4):424-447
pubmed: 27895058
Blood. 2019 Sep 19;134(12):935-945
pubmed: 31395600
N Engl J Med. 2014 Jul 24;371(4):339-48
pubmed: 25054717
Health Care Manag Sci. 2006 Aug;9(3):287-94
pubmed: 17016935
J Clin Oncol. 2011 Nov 20;29(33):4417-23
pubmed: 21969499
Lancet. 2018 Aug 18;392(10147):593-606
pubmed: 30078459
Front Oncol. 2021 Jan 15;10:603636
pubmed: 33575214
Nat Rev Clin Oncol. 2013 Aug;10(8):460-71
pubmed: 23799371
Curr Hematol Malig Rep. 2017 Dec;12(6):547-556
pubmed: 29027628
Leukemia. 2016 Jul;30(7):1456-64
pubmed: 27012865
J Clin Oncol. 2013 Nov 1;31(31):3889-97
pubmed: 24062400
Blood Adv. 2018 Jun 12;2(11):1356-1366
pubmed: 29895626
N Engl J Med. 2016 Jun 9;374(23):2209-2221
pubmed: 27276561
Biol Blood Marrow Transplant. 2018 Dec;24(12):2558-2567
pubmed: 29966760
Leukemia. 2019 May;33(5):1102-1112
pubmed: 30542144
Leukemia. 2004 Aug;18(8):1380-90
pubmed: 15201848
JAMA Netw Open. 2021 Jul 1;4(7):e2115991
pubmed: 34232303
J Clin Oncol. 2018 May 20;36(15):1486-1497
pubmed: 29601212
J Vis Exp. 2018 Mar 5;(133):
pubmed: 29553571
N Engl J Med. 2015 Sep 17;373(12):1136-52
pubmed: 26376137
Bone Marrow Transplant. 2020 Mar;55(3):669-672
pubmed: 31685932
J Clin Oncol. 2013 Nov 10;31(32):4123-31
pubmed: 24062403
Cancers (Basel). 2021 Feb 07;13(4):
pubmed: 33562393
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120
Blood. 2018 Mar 22;131(12):1275-1291
pubmed: 29330221